Radium-223 Treatment in mCRPC Patient with Polycythemia Vera

There have been several studies on the clinical outcomes of Radium-223 treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) who may have an increased risk of hematologic comorbidities. To the best of our knowledge, this is the first study to explore the potential bone m...

Descripción completa

Detalles Bibliográficos
Autores principales: de Angelis, Cristina, Frantellizzi, Viviana, Pontico, Mariano, de Feo, Maria Silvia, Lazri, Julia, de Vincentis, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2021
Materias:
Interesting Image
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522512/
https://www.ncbi.nlm.nih.gov/pubmed/34660164
http://dx.doi.org/10.4274/mirt.galenos.2020.58661
Descripción
Sumario:There have been several studies on the clinical outcomes of Radium-223 treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) who may have an increased risk of hematologic comorbidities. To the best of our knowledge, this is the first study to explore the potential bone marrow adverse effects (AEs) of Radium-223 administered with specific drugs used for hematologic conditions, such as polycythemia vera (PV). We report the case of a patient with mCRPC who was administered a combined treatment of Radium-223 and hydroxyurea for PV, aiming to support clinicians in predicting eventual AEs.

Ejemplares similares